Anti-CTLA-4 therapy for malignant mesothelioma

Guazzelli, A, Bakker, EY, Krstic-Demonacos, M, Lisanti, MP, Sotgia, F and Mutti, L 2017, 'Anti-CTLA-4 therapy for malignant mesothelioma' , Immunotherapy, 9 (3) , pp. 273-280.

[img] PDF - Accepted Version
Restricted to Repository staff only until April 2018.

Download (1MB) | Request a copy

Abstract

Immunotherapy is an emerging therapeutic strategy with a promising clinical outcome in some solid tumors, particularly metastatic melanoma. One approach to immunotherapy is immune checkpoint inhibitors, such as blockage of CTLA-4 and PD-1/PD-L1. This special report aims to describe the state of clinical trials of tremelimumab in patients with unresectable malignant mesothelioma (MM) in particular with regard to the clinical efficacy, safety and tolerability. Criticism and perspective of this treatment are also discussed. Biological and clinical considerations rule out the use of tremelimumab as single agent for MM and, more generally, the use of immune checkpoint inhibitors for MM is still largely questionable and not supported by evidences.

Item Type: Article
Schools: Schools > School of Environment and Life Sciences > Biomedical Research Centre
Journal or Publication Title: Immunotherapy
Publisher: Future Science Group
ISSN: 1750-743X
Related URLs:
Depositing User: L Mutti
Date Deposited: 06 Jun 2017 13:22
Last Modified: 08 Aug 2017 15:30
URI: http://usir.salford.ac.uk/id/eprint/42518

Actions (login required)

Edit record (repository staff only) Edit record (repository staff only)

Downloads

Downloads per month over past year